# Drug-drug Interaction Study(Lobeglitazone, Warfarin)

> **NCT02002611** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 24 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Lobeglitazone
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT02002611
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-02
- **Final completion:** 2014-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02002611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02002611, "Drug-drug Interaction Study(Lobeglitazone, Warfarin)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02002611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*